Abstract

Striatal blood flow, glucose metabolism and 18F-Dopa uptake: difference in Parkinson's disease and atypical Parkinsonism

Makoto Otsuka, Yuichi Ichiya, Shinichi Hosokawa, Yasuo Kuwabara, Takashi Tahara, Toshimitsu Fukumura, Motohiro Kato, Kouji Masuda, Ikuo Goto

Faculty of Medicine, Kyushu University, Fukuoka, Japan
Department of Radiology
M Otsuka
Y Ichiya
Y Kuwabara
T Tahara
T Fukumura
K Masuda
Department of Neurology
S Hosokawa
I Goto
Department of Neurophysiology
M Kato
Correspondence to:
Dr Otsuka,
Department of Radiology,
Faculty of Medicine,
Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812, Japan
Received 20 July 1990
and in final revised form
Accepted 24 January 1991

There are “atypical” Parkinsonian patients who do not have any specific causes for the Parkinsonian symptoms and are clinically different from idiopathic Parkinson's disease based on the lack of resting tremor and poor response to dopaminergic drugs. The pure akinetic type has been considered to be a different clinical entity from idiopathic Parkinson's disease by some investigators.1,2 Patients with atypical Parkinsonism may have other brain lesions with or without striatal dopamine depletion and are poorly responsive to levodopa.

In Parkinson's disease, regional cerebral glucose metabolism (rCMRGlc) measured with 2-18Ffluoro-2-deoxy-D-glucose (18F-FDG) have been surveyed by many investigators.3,5 Recently the levodopa analogue 6-L-fluorodopa has been labelled with 18F and a decreased uptake of 6-L-18Ffluorodopa (18F-Dopa) in the striatum has revealed the loss of dopaminergic nerve terminals in patients with Parkinson's disease in vivo.6-8 Furthermore, some studies have shown the difference of caudate 18F-Dopa uptake between Parkinson's disease and atypical Parkinsonism.9 Few reports, however, are available on the combination of glucose metabolism and 18F-Dopa uptake in Parkinson's disease and atypical Parkinsonism.

We studied blood flow and glucose metabolism in the head of the caudate and putamen separately for measuring the energy consumption as a whole in each region and 18F-Dopa uptake for measuring the function of dopaminergic nerve terminals in the head of the caudate and putamen in patients with Parkinson's disease and atypical Parkinsonism to clarify the pathophysiological similarity and difference between these conditions.

Materials and methods

Patients

Eight patients diagnosed clinically as Parkinson's disease and eight with atypical Parkinsonism were studied (table 1). Patients were clinically classified in stage I, II or III from Hoehn and Yahr,10 and none of them was demented. All patients with Parkinson's disease had the three classic signs of resting tremor, rigidity, and akinesia with no pyramidal signs, and responded well to levodopa. Patients with atypical Parkinsonism were classified into either the akinetic type or the akinetic rigid type. There might be a criticism that patients with atypical Parkinsonism were not classified into specific diseases or syndromes, however, most cases with atypical Parkinsonism were in the early stages of their disease and could not be categorised more precisely. Cases 9 and 10 with atypical Parkinsonism showed only akinesia without resting tremor nor rigidity. Case 11 had akin-
Table 1  Clinical features of patients with Parkinson's disease (PD) (1-8) and patients with atypical Parkinsonism (PKM) (9-16)

<table>
<thead>
<tr>
<th>Case number</th>
<th>PD</th>
<th>PKM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Age/Sex</td>
<td>Treatmentb</td>
</tr>
<tr>
<td>1</td>
<td>37/F, 41/M</td>
<td>Decreased dysarthria</td>
</tr>
<tr>
<td>2</td>
<td>52/M, 53/M, 47/M</td>
<td>NE</td>
</tr>
<tr>
<td>3</td>
<td>56/F</td>
<td>NE</td>
</tr>
<tr>
<td>4</td>
<td>50/F</td>
<td>NE</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>*</td>
</tr>
<tr>
<td>6</td>
<td>2</td>
<td>**</td>
</tr>
<tr>
<td>7</td>
<td>3</td>
<td>**</td>
</tr>
<tr>
<td>8</td>
<td>4</td>
<td>+</td>
</tr>
<tr>
<td>9</td>
<td>1</td>
<td>NE</td>
</tr>
<tr>
<td>10</td>
<td>2</td>
<td>NE</td>
</tr>
<tr>
<td>11</td>
<td>3</td>
<td>NE</td>
</tr>
<tr>
<td>12</td>
<td>4</td>
<td>NE</td>
</tr>
<tr>
<td>13</td>
<td>5</td>
<td>NE</td>
</tr>
<tr>
<td>14</td>
<td>6</td>
<td>NE</td>
</tr>
<tr>
<td>15</td>
<td>7</td>
<td>NE</td>
</tr>
<tr>
<td>16</td>
<td>8</td>
<td>NE</td>
</tr>
</tbody>
</table>

*---marked; **---moderate; +---mild; ---absent; 4From Hoehn and Yahr**; 0---no treatment; D---levodopa; P---bromocriptine, pergolide; M---amantadine; A---anticholinergic; E---effective; NE---not effective; *postural tremor; neck rigidity.

Tremor +
CE-effective;
Age/Sex

Dysarthria

Clinical stage'

Case number
Striatal
Cortical

1
-
-
-
-
-
-
-
-
-
-
-
2
**
**
-
-
-
-
-
-
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
-
-
-
-
-
-
-
-
-
-
5
-
-
-
-
-
-
-
-
-
-
-
-
6
-
-
-
-
-
-
-
-
-
-
-
-
7
-
-
-
-
-
-
-
-
-
-
-
-
8
-
-
-
-
-
-
-
-
-
-
-
-

---marked; **---moderate; +---mild; ---absent; 4From Hoehn and Yahr**; 0---no treatment; D---levodopa; P---bromocriptine, pergolide; M---amantadine; A---anticholinergic; E---effective; NE---not effective; *postural tremor; neck rigidity.

by walking difficulty, dysarthria and postural tremor. Postural tremor was dominant in his left hand. On examination he showed mild cogwheel rigidity in his limbs and postural hypotension (112/80 mmHg in supine position, 80/60 standing). He also showed impaired fine finger movement and adiadochokinesis. Deep tendon reflexes were increased and a Babinski's sign was present bilaterally.

Case 14 A 74 year old man started to complain of difficulty in handwriting at the age of 73. This was followed by walking difficulty and a tendency to fall. He also noticed dysarthria. On examination he showed mild rigidity of the limbs. No postural hypotension was observed. His fine finger movement and coordination was mildly disturbed.

Case 15 A 48 year old man complained of clumsiness in the right hand at the age of 44. This was followed by short shuffling steps when walking. He also developed dysarthria. On examination he showed marked cogwheel rigidity of extremities. No postural hypotension was observed. His fine finger movement and coordination was mildly disturbed in the right side and slightly disturbed in the left side.

Case 16 A 71 year old man complained of postural tremor of both hands at the age of 67. This was followed by walking difficulty and dysarthria. On examination he showed moderate cogwheel rigidity of the limbs. No postural hypotension was observed.

Cases 1, 2, 11, 13 and 14 had received no treatment before the PET examination. The other cases received medication before the PET examination as shown in table 1, and medication was stopped at least 48 hours before the examination.

The 18F-Dopa uptake was measured in all cases except for cases 14 and 16, and regional cerebral blood flow (rCBF) was measured in all cases except for cases 13, 14 and 16. The rCMRGlc was measured in all cases except for cases 4 and 15.

For comparison, eight, mean (SD) age, 47-3 (15-8) years, eight, mean (SD) age, 49-6 (14-0) years, and seven, mean (SD) age, 52-1 (13-6)
years, normal volunteers had dopamine, rCBF and rCMRGlc studies, respectively. The volunteers had no neurological deficit and CT scans without abnormality were taken in the volunteers over 50 years old.

Methods

PET was performed with a HEADTOME III (Shimadzu Corporation, Japan) at a spacial solution of 8.2 mm full width at half maximum (FWHM). A transmission scan with a $^{68}$Ge/$^{68}$Ga ring source was obtained for correction of attenuation. Five slices were taken in the orbitomeatal line (OM) +2 cm, +3.5 cm, +5 cm, +6.5 cm and +8 cm planes by a single scanning. The region of interest (ROI) for cerebellar hemisphere was sited in the OM +2 cm plane with a 1.4 x 1.8 cm rectangle. The ROIs of the head of the caudate and putamen were outlined visually on the $^{18}$F-Dopa image by reference to the glucose or blood flow image and also the images of CT and/or MRI. They were generally sited in the OM +5 cm plane, but another five slices in the OM +2.7 cm, +4.2 cm, +5.7 cm, +7.2 cm and +8.7 cm planes were also taken and the most appropriate slice level of caudate head and putamen was sought. The ROI to the cerebral hemisphere was outlined visually on the glucose or blood flow image in the third slice, and excluded caudate and putamen to obviate the striatal difference among the groups (fig 1).

Two to seven mCi (54 to 260 MBq) of $^{18}$F-Dopa was injected intravenously and PET data was obtained every two minutes for 20 minutes, every four minutes for 40 minutes and at 70, 90, 120 minutes for 15 minutes. The tissue activity of $^{18}$F in the bilateral caudate and putamen was corrected by the non-specific retention of $^{18}$F in cerebellar hemispheres. The ratio of caudate or putamen to cerebellum increased steadily with time for 120 minutes after the injection (fig 2) and the ratio of caudate or putamen to cerebellum at 120 minutes was calculated.

The rCBF was measured just before the $^{18}$F-Dopa study by the oxygen-15 steady state technique, using continuous inhalation of 100 mCi (3.7 GBq) of oxygen-15 labelled carbon dioxide. Arterial blood sampling was performed from a catheter in the femoral artery four times during six minutes of emission scan.

The rCMRGlc was measured on a different day within a week from the $^{18}$F-Dopa and CBF study using $^{18}$F-FDG. Three to seven mCi (110 to 260 MBq) of $^{18}$F-FDG was injected intravenously, and arterial blood samples were obtained at predetermined intervals from the time of injection until the end of scanning. The rCMRGlc was determined from the emission scan and blood curve data by using the model of Sokoloff et al and Phelps et al later modified by Brooks.

Significant clinical asymmetry was observed in cases 1, 2, 3, 9, 13 and 15, and $^{18}$F-Dopa uptake was decreased more in the contralateral side in all of them. As no significant asymmetry in the clinical features and in the $^{18}$F-Dopa uptake was observed in all the other cases, values were calculated as the mean of the

![Figure 1](Fig1.png) The region of cerebellar hemisphere in the OM + 2 cm plane (rCe, lCe), and that of the head of the caudate (rC, lC), putamen (rP, lP) and global cerebral hemisphere (excluding caudate head and putamen) (rH, lH) in the OM + 5 cm plane. Upper two figures are images of rCMRGlc and lower two figures are images of $^{18}$F-Dopa uptake.

<table>
<thead>
<tr>
<th>Case number</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{18}$F-Dopa uptakea</td>
<td>C</td>
<td>2.68</td>
<td>2.48</td>
<td>2.06</td>
<td>2.25</td>
<td>2.03</td>
<td>1.84</td>
<td>1.84</td>
<td>1.93</td>
<td>2.14</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>1.97</td>
<td>2.23</td>
<td>1.73</td>
<td>1.77</td>
<td>1.35</td>
<td>1.60</td>
<td>1.56</td>
<td>1.61</td>
<td>1.73</td>
</tr>
<tr>
<td>CBFb</td>
<td>C</td>
<td>45.1</td>
<td>38.5</td>
<td>31.6</td>
<td>37.9</td>
<td>40.4</td>
<td>31.0</td>
<td>35.8</td>
<td>40.8</td>
<td>37.6</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>46.2</td>
<td>43.9</td>
<td>37.5</td>
<td>36.7</td>
<td>38.0</td>
<td>37.4</td>
<td>40.3</td>
<td>44.9</td>
<td>40.6</td>
</tr>
<tr>
<td></td>
<td>GC</td>
<td>36.6</td>
<td>33.7</td>
<td>30.8</td>
<td>30.8</td>
<td>30.5</td>
<td>31.8</td>
<td>29.6</td>
<td>32.7</td>
<td>32.7</td>
</tr>
<tr>
<td>CMRGlc*</td>
<td>C</td>
<td>7.50</td>
<td>7.79</td>
<td>7.76</td>
<td>6.98</td>
<td>8.90</td>
<td>8.01</td>
<td>7.32</td>
<td>7.75</td>
<td>0.61</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>8.64</td>
<td>8.55</td>
<td>8.18</td>
<td>7.29</td>
<td>8.41</td>
<td>8.87</td>
<td>8.82</td>
<td>8.39</td>
<td>0.54</td>
</tr>
<tr>
<td></td>
<td>GC</td>
<td>6.96</td>
<td>6.29</td>
<td>6.18</td>
<td>5.47</td>
<td>6.51</td>
<td>5.96</td>
<td>5.79</td>
<td>6.31</td>
<td>0.51</td>
</tr>
</tbody>
</table>

*Otsuka, Ichiya, Horokawa, Kusabara, Tahara, Fukumura, Kato, Masuda, Goto

Table 2 PET results in patients with Parkinson's disease (PD) (1-8) and patients with atypical Parkinsonism (PKM) (9-16)

- C—caudate; P—putamen; GC—global cerebrum (excluding caudate and putamen); (mean ratio to cerebellum; ml/min/100 ml; mg/min/100 ml.

---

Translated by a language model.
bilateral sides generally and values for the more decreased side in the \(^{18}\)F-Dopa uptake were evaluated in cases 1, 2, 3, 9, 13 and 15.

Results

Time courses of radioactivity on the ratio of caudate to cerebellum and putamen to cerebellum in normal controls, patients with Parkinson's disease stage I and II, and patients with Parkinson's disease stage III (PD III). Means and SDs are generally shown except where deviation bars are omitted for clarity.

---

### Table 1

<table>
<thead>
<tr>
<th>PKM</th>
<th>Akinesic type</th>
<th>Akinesic rigid type</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9</td>
<td>10</td>
<td>11</td>
</tr>
<tr>
<td>PKM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PKM</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

Figure 2 Time courses of radioactivity on the ratio of the head of the caudate to cerebellum (a), and that on the ratio of putamen to cerebellum (b) in normal controls, patients with idiopathic Parkinson's disease stage I and II (PD I, II) and patients with Parkinson's disease stage III (PD III). Means and SDs are generally shown except where deviation bars are omitted for clarity.

Figure 3 The \(^{18}\)F-Dopa uptake ratio of the caudate to cerebellum (C) and putamen to cerebellum (P) at 120 minutes after the administration in controls, patients with Parkinson's disease (PD) and patients with atypical Parkinsonism (PKM). Means and SDs are shown. **, * indicate significant difference between the two indicated groups by Scheffe's F-test (* * * p < 001, * p < 05, NS: not significant).

---

were shown in table 2. The uptake ratio of the caudate to cerebellum and the putamen to cerebellum at 120 minutes after the administration of \(^{18}\)F-Dopa in patients with Parkinson's disease and atypical Parkinsonism were compared with normal controls in fig 3. Decreased \(^{18}\)F-Dopa uptake in both regions was observed in patients with Parkinson's disease and atypical Parkinsonism compared with normal controls (p < 01) by Scheffe's F-test, however, the caudate \(^{18}\)F-Dopa uptake in Parkinson's disease was relatively spared. The \(^{18}\)F-Dopa uptake in the putamen decreased more than that in caudate significantly in Parkinson's disease by \(t\) test (p < 01). There was no statistical differences in the putaminal \(^{18}\)F-Dopa uptake between Parkinson's disease and atypical Parkinsonism.

There was no significant difference in the rCBF of the caudate and putamen in patients with Parkinson's disease compared with controls, but the rCBF of both regions in patients with atypical Parkinsonism decreased in comparison with controls (p < 01) and patients with Parkinson's disease (p < 01) (fig 4). The rCBF of the global cerebrum (excluding the caudate and putamen) in patients with atypical Parkinsonism as well as that of the caudate and putamen decreased in comparison with con-
trols (p < 0.01) and patients with Parkinson's disease (p < 0.01) (table 2). The rCMRGlc of caudate and putamen also decreased significantly in patients with atypical Parkinsonism compared with controls (p < 0.01) and patients with Parkinson's disease (p < 0.01) (fig 5). The rCMRGlc of the global cerebrum in patients with atypical Parkinsonism also decreased in comparison with controls (p < 0.01) and patients with Parkinson's disease (p < 0.01) (table 2).

Images of $^{18}$F-Dopa uptake at 120 minutes after injection (obtained by the PET data from 112 to 127 minutes after injection), rCBF and rCMRGlc at a level of the striatum in a control subject, in a patient with Parkinson's disease (Case 5) and in a patient with atypical Parkinsonism (Case 11) are shown in figs 6a, b, and c, respectively.

Discussion
Decreased $^{18}$F-Dopa uptake in the putamen in patients with Parkinson's disease measured by PET in this study and in previous reports is coincident with the dopamine depletion probably due to the hypofunction or decreased retention capacity of dopamine in dopaminergic nerve terminals in the putamen. Decreased but relatively spared $^{18}$F-Dopa uptake in the head of the caudate in patients with Parkinson's disease is also coincident with the previous PET studies as well as with the previous neurochemical studies showing that dopamine levels are depressed more in the putamen than in the caudate in Parkinson's disease.

On the other hand, equally decreased $^{18}$F-Dopa uptake in the putamen and in the caudate in atypical Parkinsonism seems to reflect the different pathogenesis of Parkinson's disease and atypical Parkinsonism.

The unchanged rCBF and rCMRGlc in the putamen and caudate from normal controls, assuming that there was no change in the striatal energy consumption as a whole, in patients with Parkinson's disease was also shown in this study. Preserved function of dopaminergic receptors has been measured by PET using $^{11}$C-N-methylpiperone in patients with Parkinson's disease, and hypometabolism of only dopaminergic nerve terminals might not affect the total metabolism of the putamen or caudate. Some reported increased striatal CMRGlc and others decreased striatal CMRGlc in patients with Parkinson's disease. This inconsistency with our study and the others may be due to the different clinical stages at which the PET study was carried out. Patients with Parkinson's disease in our study were in the relatively early stages and not demented, while we have a different result of decreased global cerebral glucose metabolism in demented patients with Parkinson's disease (Hosokawa et al, in preparation).

Cases 9, 10, and 11 were not responsive to levodopa and showed symptoms of pure akinesia without resting tremor nor rigidity. This "pure akinesic" type may be a different clinical entity from Parkinson's disease, in which a part of early phases of progressive supranuclear palsy (PSP) may be included. Although the relationship between pure akinesia and PSP remains unclear, PET results in the previous reports of decreased striatal CBF, oxygen and glucose metabolism in patients with PSP are similar to the present study of rCBF and rCMRGlc in patients with atypical Parkinsonism. Akineti rigid syndrome may be part of a spectrum of multiple system atrophy (MSA). Cases 12 and 16 may be close to striatonigral degeneration (SND), case 13 was diagnosed as Shy-Drager's syndrome, and cases 14 and 15 had additional cerebellar symptoms and signs and may be the early phase of olivopontocerebellar atrophy (OPCA). PET studies in patients with SND showed decreased striatal glucose metabolism, which was consistent with our results in patients with atypical Parkinsonism. The clinical diagnosis of atypical Parkinsonism may be replaced by the final diagnosis after specific symptoms and signs develop. The differentiation from Parkinson's disease can be clinically performed and is of practical importance.

A decrease of rCBF and rCMRGlc in the caudate and putamen in patients with atypical Parkinsonism (in spite of no focal abnormalities in the striatum on CT and/or MRI), suggests the impairment of the total neuronal activity in the striatum, including the hypofunction of striatal non-dopaminergic neurons since the dopaminergic neurons comprise 10% or less of the striatal neurons from histological study of
Striatal blood flow, glucose metabolism and $^{18}$F-Dopa uptake: difference in Parkinson's disease and atypical Parkinsonism

Figure 6. Images of $^{18}$F-Dopa uptake at 120 minutes after injection (a), rCBF (b) and rCMRGlc (c) at a level of the striatum in a control subject, in a patient with Parkinson's disease (PD) (case 5) and in a patient with atypical Parkinsonism (PKM) (case 11). Striatal $^{18}$F-Dopa uptake decreased in PD and PKM compared with that in a control. The $^{18}$F-Dopa uptake in caudate in PD seemed relatively spared in comparison with that in putamen (a). The rCBF and rCMRGlc in global cerebrum including the caudate and putamen decreased in PKM compared to those in control and PD (b, c).

The rat. Furthermore, a decrease of rCBF and rCMRGlc in the cerebrum suggests the hypofunction of not only the caudate and putamen but also of the cerebrum in patients with atypical Parkinsonism.

There was no dissociation between rCBF and rCMRGlc in this study and we have previously observed good coupling between rCBF, rCMRO$_2$ and rCMRGlc in PSP patients. This is because all the patients in this study and in the previous report were in the chronic state.

In conclusion, our study has shown the different PET results between idiopathic Parkinson's disease and atypical Parkinsonism.

1) Decreased $^{18}$F-Dopa uptake in the caudate and putamen with relative sparing of the caudate in patients with idiopathic Parkinson's disease, and equally decreased $^{18}$F-Dopa uptake in the caudate and putamen in patients with atypical Parkinsonism.

2) Normal rCBF and rCMRGlc in patients with Parkinson's disease and decreased rCBF and rCMRGlc of the caudate and putamen associated with global cerebral decrease in patients with atypical Parkinsonism. These results may underlie the similarity and the difference in the pathophysiological mechanism of idiopathic Parkinson's disease and atypical Parkinsonism.

We thank Dr R Gunasekera for editorial assistance. This study was partly supported by Grant 62-10 from the Japanese Ministry of Health and Welfare and Grant-in-Aid 63570493 for Scientific Research from the Japanese Ministry of Education, Science and Culture.